Haemophilia A News and Research

RSS

Hemophilia A is an X-linked, recessive, bleeding disorder caused by a deficiency in the activity of coagulation factor VIII. Affected individuals develop a variable phenotype of hemorrhage into joints and muscles, easy bruising, and prolonged bleeding from wounds. The disorder is caused by heterogeneous mutations in the factor VIII gene which maps to Xq28.

FDA approves Norditropin for short stature in children with Noonan syndrome

Novo Nordisk has announced that Norditropin (somatropin[rDNA origin] injection) received U.S. Food and Drug Administration (FDA) approval for the treatment of short stature in children with Noonan syndrome.

3 Jun 2007

Study finds large number of new proteins implicated in Huntington's disease

Researchers from four organizations have identified more than 200 new proteins that bind to normal and mutant forms of the protein that causes Huntington's disease (HD).

11 May 2007

New treatments for brain hemorrhage

The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.

4 May 2007

FDA approves new treatment for von Willebrand disease

The U.S. Food and Drug Administration (FDA) has approved Humate-P (Antihemophilic Factor/von Willebrand Factor Complex) for the prevention of excessive bleeding during and after surgery in certain patients with mild to moderate and severe von Willebrand disease (vWD).

30 Apr 2007

Muscle restoration in an animal model of Duchenne muscular dystrophy

Using a new type of drug that targets a specific genetic defect, researchers at the University of Pennsylvania School of Medicine, along with colleagues at PTC Therapeutics Inc. and the University of Massachusetts Medical School, have for the first time demonstrated restoration of muscle function in a mouse model of Duchenne's muscular dystrophy (DMD).

24 Apr 2007

Scientists tackle cancer with different approaches

Studies presented at the 2007 meeting of the American Association for Cancer Research show how researchers are using the new, as well as the natural, to help design and test new drugs to treat cancer.

18 Apr 2007

Fragile X and Down syndrome appear to share common genetic cause

The two most prevalent forms of genetic mental retardation, Fragile X and Down syndromes, may share a common cause, according to researchers at Stanford University School of Medicine.

11 Apr 2007

Bayer Healthcare Pharmaceuticals launches in the U.S.

Bayer HealthCare Pharmaceuticals Inc. today announced its official U.S. launch. The new company incorporates the former Berlex Inc.into Bayer HealthCare Pharmaceuticals, as part of Bayer's acquisition of Schering AG, Germany, Berlex's former parent company.

5 Apr 2007

Increasing numbers of blood collection centers in parts of China contributing to spread of HIV

The increasing number of blood-collection centers in parts of China is posing a threat to vulnerable populations and placing them at an increased risk of HIV transmission, some Chinese HIV/AIDS advocates have said recently, the Boston Globe reports.

4 Mar 2007

Apolipoprotein C1 protein linked to elevated BMI in people of American Indian and Mexican ancestry

University of Minnesota researchers have discovered a variant of a common blood protein, apolipoprotein C1, in people of American Indian and Mexican ancestry that is linked to elevated body mass index (BMI), obesity and Type 2 diabetes.

22 Feb 2007

Alphanate approved to treat Von Willebrand disease

The U.S. Food and Drug Administration (FDA) has announced the approval of Antihemophilic Factor/von Willebrand Factor Complex (Human), Alphanate.

4 Feb 2007

EDMA welcomes 7 new members

EDMA, the European Diagnostic Manufacturers Association, enlarges its membership with six new companies: BioSystems SA, Diagnostica Stago, Innogenetics, Luminex Corporation, Orion Diagnostica and Tecan, and the Foundation for Innovative New Diagnostics (FIND).

9 Jan 2007

Army docs use of dangerous drug labelled irresponsible and inappropriate

American soldiers critically wounded in Iraq are being treated with a potent, experimental, blood-coagulating drug despite evidence it can cause clots in the lungs, heart and brain, leading to strokes, heart attacks and death.

20 Nov 2006

Potential permanent genetic cure for hemophilia A

A discovery by Medical College of Wisconsin and BloodCenter of Wisconsin researchers in Milwaukee may be a key to a permanent genetic cure for hemophilia A patients, including a subset who do not respond to conventional blood transfusions.

3 Jul 2006

Convictions in $45 million illegal blood diversion scheme

Florida pharmaceutical wholesale distributor, convicted on March 29, 2006, of more than two hundred and forty-seven criminal counts as the result of an extensive OCI investigation of an illegal medical products diversion scheme which defrauded the Medicaid and Medicare programs of more than $45,000,000.

19 Apr 2006

Weill Cornell experts publish review of genetic medicine

In an article published in the April issue of Nature Reviews Genetics, two experts at the Weill Medical College of Cornell University sum up the achievements, challenges and promise of a burgeoning field: genetic medicine.

3 Apr 2006

Rapamycin (sirolimus) may be effective in treating kidney disease

A widely available drug may be effective in treating kidney disease, report scientists at the University of California, Santa Barbara. They describe the discovery in the online edition of the Proceedings of the National Academies of Science.

21 Mar 2006

Ancient DNA helps unearth potential hemophilia therapy

A cut can be life-threatening for people with hemophilia, whose bodies don't produce enough of a protein that prevents prolonged bleeding.

1 Mar 2006

Emerging infectious agents pose new risks for people with bleeding disorders

An international team of scientists, including a hematologist from Thomas Jefferson University in Philadelphia, has concluded that people with bleeding disorders such as hemophilia remain at risk from emerging infectious agents in plasma and blood transfusions. For this reason, recombinant therapies, that is, those produced in the laboratory, must always be an option

16 Feb 2006

Cellular discovery suggests possibilities for drug therapy for kidney disease

Scientists at the University of California, Santa Barbara have reported a discovery at the cellular level that suggests possibilities for drug therapy for kidney disease.

13 Feb 2006